0001019687-15-000190.txt : 20150114 0001019687-15-000190.hdr.sgml : 20150114 20150114160613 ACCESSION NUMBER: 0001019687-15-000190 CONFORMED SUBMISSION TYPE: NT 10-Q PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20141130 FILED AS OF DATE: 20150114 DATE AS OF CHANGE: 20150114 EFFECTIVENESS DATE: 20150114 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Cannabics Pharmaceuticals Inc. CENTRAL INDEX KEY: 0001343009 STANDARD INDUSTRIAL CLASSIFICATION: METAL MINING [1000] IRS NUMBER: 203373669 STATE OF INCORPORATION: NV FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: NT 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 000-52403 FILM NUMBER: 15527304 BUSINESS ADDRESS: STREET 1: #3 BETHESDA METRO CENTER STREET 2: SUITE 700 CITY: BETHESDA STATE: MD ZIP: 20814 BUSINESS PHONE: 877-424-2429 MAIL ADDRESS: STREET 1: #3 BETHESDA METRO CENTER STREET 2: SUITE 700 CITY: BETHESDA STATE: MD ZIP: 20814 FORMER COMPANY: FORMER CONFORMED NAME: American Mining Corp DATE OF NAME CHANGE: 20110510 FORMER COMPANY: FORMER CONFORMED NAME: Thrust Energy Corp. DATE OF NAME CHANGE: 20051031 NT 10-Q 1 cannabics_ext.htm NOTICE OF LATE FILING

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

___________________

 

CANNABICS PHARMACEUTICALS INC.

(Full Name of Registrant)

 

FORM 12b-25

 

NOTIFICATION OF LATE FILING

 

SEC FILE NUMBER: 333-192759

 

(Check One): [_] Form 10-K       [_] Form 20-F       [_] Form 11-K      [X] Form 10-Q       [_] Form N-SAR

 

For Period Ended: November 30th, 2014


[_] Transition Report on Form 10-K
[_] Transition Report on Form 20-F
[_] Transition Report on Form 11-K
[_] Transition Report on Form 10-Q
[_] Transition Report on Form N-SAR

For the Transition Period Ended: _________________

 

Nothing in this form shall be construed to imply that the Commission has verified any information contained herein. If the notification relates to a portion of the filing checked above, identify the Item(s) to which the notification relates:

 

PART I - REGISTRATION INFORMATION

 

CANNABICS PHARMACEUTICALS INC.

 (Exact name of registrant as specified in its charter)

___________________________________________________

 

Nevada 333-192759 20-3373669
(State of incorporation) (Commission File Number) (IRS Employer No.)

 

#3 Bethesda Metro Center

Suite 700

Bethesda, Md 20814

(Address of principal executive offices and Zip Code)

 

877 424-2429

(Registrant's telephone number, including area code)

 

 

1
 

 

PART II - RULE 12b-25(b)

 

If the subject report could not be filed without unreasonable effort or expense and the registrant seeks relief pursuant to Rule 12b-25(b), the following should be completed. (Check box if appropriate)

 

[X] (a) The reasons described in reasonable detail in Part III of this form could not be eliminated without unreasonable effort or expense;

 

[X] (b) The subject annual report on Form 10-K will be filed on or before the fifteenth calendar day following the prescribed due date; or the subject quarterly report or transition report on Form 10-Q, or portion thereof will be filed on or before the fifth calendar day following the prescribed due date.

 

PART III - NARRATIVE

 

The Registrant's quarterly report on Form 10-K could not be filed within the prescribed time period because the Registrant encountered delays in its preparation of its quarterly financial statements.

 

PART IV - OTHER INFORMATION

 

(1) Name and telephone number of person to contact in regard to this notification.

 

Dr. Zohar Koren
(Name)
 
(877) 424-2429
(Area Code) (Telephone Number)

 

(2) Have all other periodic reports required under Section 13 or 15(d) of the Securities Exchange Act of 1934 or Section 30 of the Investment Company Act of 1940 during the preceding 12 months or for such shorter period that the registrant was required to file such report(s) been filed? If answer is no, identify report(s).

 

[X] Yes [_] No

 

(3) Is it anticipated that any significant changes in results of operations from the corresponding period for the last fiscal year will be reflected by the earnings statements to be included in the subject report or portion thereof?

 

[_] Yes [X] No

 

If so, attach an explanation of the anticipated change, both narratively and quantitatively, and, if appropriate, state the reasons why a reasonable estimate of the results cannot be made.

 

Cannabics Pharmaceuticals Inc.
Name of Registrant as Specified in Charter

 

has caused this notification to be signed on its behalf by the undersigned hereunto duly authorized.

 

By: Dr. Zohar Koren,  Dir.
Date:  January 14th, 2015
/s/ Dr. Zohar Koren

 

 

2